Histopathology Services Market

Histopathology Services Market is expected to grow at a CAGR of 5.7% from 2021 to 2028.

Histopathology services are used in the examination of biological tissues for the diagnosis of diseases. The procedure includes microscopic examination of tissues. With the help of imaging techniques biopsy tissues can now be obtained from certain inaccessible sites such as pancreas and the peritoneum.

BD and 3M – Notable Market Players in Histopathology Services Market

The histopathology services market majorly consists of the players such as Sonic Healthcare Limited, Laboratory Corporation of America Holdings, Acculabs Diagnostics UK Ltd, TPL Path Labs, UNILABS, Cureline Global Translational CRO, Targos, Cellular Pathology Services, Experimental Pathology Laboratories Inc (EPL), and CHARLES RIVER LABORATORIES, INC. among others. The companies have been implementing various strategies that have helped the growth of the company and in turn have brought about various changes in the market. The companies have adopted several inorganic and organic strategies to accelerate their growth and improve their market position.

Below is the list of the growth strategies done by the players operating in the histopathology services market:

Year News
May-21 Discovery Life Sciences (Discovery), has acquired Targos Molecular Pathology GmbH, Germany (Targos), to significantly expand its global tissue biomarker services. The addition of Targos immediately expands Discovery’s capabilities on a global scale to support our customers’ tissue biomarker programs for every stage of research.
Apr-21 Telemedicine Clinic (A Unilabs Company), in partnership with Alliance Medical and Doncaster Clinical Commissioning Group (CCG), has started providing reporting services for low dose CT scans as part of the UK NHS’s Targeted National Lung Health Check program.
Oct-2020 StageBio, a leading provider of GLP-compliant necropsy, histology, pathology and specimen archiving services for both preclinical and clinical research, has acquired its acquisition of TPL Path Labs of Freiburg, Germany. The combined organization offers an expanded array of histopathology, molecular pathology, toxicology, digital image analysis and related solutions to biopharma, medical device and academic researchers across the U.S., Europe and beyond. StageBio is a portfolio company of Ampersand Capital Partners.



Leave a Reply

Your email address will not be published. Required fields are marked *